Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Coya TherapeuticsCOYA -3.10%49 3-Year EBITDA Growth Rate is 29.10% as of Jun. 2026, which is 325% above its 10-year median of 6.85. GuruFocus rates COYA with a GF Score™ of 49/100 and a GF Value™ of $6.54 (Significantly Undervalued). Among 1,127 Biotechnology companies, Coya Therapeutics ranks better than 65.84% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 29.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 6 years, the highest 3-Year average EBITDA Per Share Growth Rate of Coya Therapeutics was 29.10% per year. The lowest was -15.40% per year. And the median was 6.85% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Coya Therapeutics 3-Year EBITDA Growth Rate Related Terms
COYA vs ONCY, GUTS, SEER: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Coya Therapeutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Coya Therapeutics 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Coya Therapeutics's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Coya Therapeutics's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 29.10% mean?
Coya Therapeutics (COYA) has a 3-Year EBITDA Growth Rate of 29.10% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Coya Therapeutics and its competitors. This is 325% above median its historical median of 6.85. According to the industry distribution chart, Coya Therapeutics ranks #385 out of 1127 companies in the Biotechnology industry, placing it in the top 34.2%.
Is Coya Therapeutics' 3-Year EBITDA Growth Rate too high?
Coya Therapeutics' current 3-Year EBITDA Growth Rate of 29.10% is 325% above median its 10-year median of 6.85. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.60. Coya Therapeutics' value of 29.10% is 99.3% above this industry median. Based on the distribution chart, Coya Therapeutics ranks #385 out of 1127 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Coya Therapeutics has a GF Score™ of 49/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Coya Therapeutics' 3-Year EBITDA Growth Rate compare to ONCY and GUTS?
According to the Biotechnology industry distribution chart, Coya Therapeutics ranks #385 out of 1127 companies for 3-Year EBITDA Growth Rate. This puts Coya Therapeutics in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.60. Coya Therapeutics' value of 29.10% is 99.3% above this benchmark. While the company's 10-year median is 6.85 vs. the industry median of 14.60, Coya Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.60, based on 1,127 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Coya Therapeutics's current 3-Year EBITDA Growth Rate of 29.10% is 99.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Coya Therapeutics and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Coya Therapeutics's current 3-Year EBITDA Growth Rate is 29.10%, which is 325% above median its own 10-year median of 6.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coya Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Coya Therapeutics (COYA) is currently considered Significantly Undervalued. The stock's GF Value™ is $6.54, compared to a current price of $4.39 — trading 32.9% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 29.10%, which is 325% above median its 10-year median of 6.85 and 99.3% above the Biotechnology industry median of 14.60. Coya Therapeutics' overall GF Score™ is 49/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Coya Therapeutics (COYA), the current 3-Year EBITDA Growth Rate is 29.10% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Coya Therapeutics (COYA) Overvalued in 2026?
Based on GuruFocus' analysis, Coya Therapeutics stock appears to be undervalued.
The current stock price of $4.39 is trading 32.9% below its estimated GF Value™ of $6.54.
GuruFocus considers Coya Therapeutics to be Significantly Undervalued.
Key valuation signals for COYA:
3-Year EBITDA Growth Rate: 29.10% (325% above median its 10-year median of 6.85)
GF Value™: $6.54 vs. price of $4.39 (32.9% below fair value)
Industry Position: 99.3% above the Biotechnology median (#385 of 1127)
No single metric tells the full story. See the COYA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells (Tregs). The company's initial development programs are focused on neurodegenerative, chronic inflammatory, autoimmune, and metabolic diseases with high unmet medical needs.
49GF Score
Get the complete analysis for COYA
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
COYA has been successfully added to your 
